Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), has greatly improved the treatment and prognosis of chronic myeloid leukemia (CML) [5]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.